In a 71-week double-blind, placebo-controlled trial, 27.9% of participants with overweight or obesity taking oral semaglutide 25 mg lost 20% body weight at week 64, compared to 3.1% of the placebo group
The choice between semaglutide and tirzepatide depends on individual response patterns, tolerability, and genetic peptide-pathway signaturesfactors the Precision Peptide Genetic Test helps clarify for long-term success
People with a history of medullary thyroid cancer, gallbladder disease or pancreatitis, as well as those with multiple endocrine neoplasia syndrome type 2 should avoid taking these drugs
Larsen, J., Hylleberg, B., Ng, K
Once a peptide molecule unfolds, returning it to the correct temperature does not refold it
These medications are synthetic analogs or mimetics of human GLP-1 that resist degradation by the enzyme dipeptidyl peptidase-4 (DPP-4), allowing for prolonged therapeutic action